Diagnostics Groups Support Risk-Based Regulatory Regime In Europe
This article was originally published in The Gray Sheet
Executive SummaryRespondents to a European Commission survey, including diagnostics makers and clinical labs, support the creation of a new, risk-based classification system for in vitro diagnostic devices in Europe.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.